Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin cancer study digs into patient data to spot trends

NCT ID NCT07538960

Knowledge-focused Sponsor: Caja Costarricense de Seguro Social Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks back at the medical records of 350 adults diagnosed with cutaneous T-cell lymphoma, a rare type of skin cancer, treated at Hospital México in Costa Rica between 2019 and 2025. Researchers aim to describe the patients' backgrounds, the treatments they received, and their outcomes. No new treatments are being tested; instead, the goal is to gather information that could help improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

he study population will consist of adult patients (≥18 years) of both sexes with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, and documented in EDUS at the Dermatology Service of Hospital México between January 2019 and December 2025. Patients must have at least one recorded dermatological evaluation during the study period and must have received some form of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic therapies. Patients with insufficient or incomplete clinical records that prevent adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution will be excluded, as well as those with a presumptive diagnosis without histopathological confirmation, duplicate or inconsistent records, patients attended outside the study period, those outside the defined age range, and patients.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025. * Patients aged 18 years or older, of both sexes. * Patients with at least one dermatological evaluation recorded during the study period. * Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments. Exclusion Criteria: * Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution. * Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation. * Duplicate or inconsistent records that hinder the correct identification and classification of the patient. * Patients attended outside the established study period. * Patients outside the age range. * Patients who do not belong to the Dermatology Service of Hospital México.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cutaneous are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymph node cancer primary cutaneous T-cell non-Hodgkin lymphoma skin disorder T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cutaneous Lymph node cancer T-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital México

    San José, Uruca, 10107, Costa Rica

More trials for these conditions

Other studies related to the condition(s) this trial covers.